Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Samuel Isaly’s OrbiMed Advisors Discloses Large Stake in Glaukos Corp (GKOS) After Its IPO

Glaukos Corp (NYSE:GKOS) is an $870 million developer of products for the treatment of glaucoma, which conducted its IPO last week with 6.90 million shares at $18.00 per unit. Among the initial backers of the company is Sam Isaly’s OrbiMed Advisors, which disclosed holding 2.90 million common shares obtained through the conversion of Series D Convertible Preferred Stock and Series F Convertible Preferred Stock and warrants. The position amasses close to 10% of the company’s outstanding stock. Prior to the IPO, OrbiMed held around 11.7% of the outstanding shares.

Samuel Isaly Orbimed Advisors

Since the stock of Glaukos Corp (NYSE:GKOS) started trading on June 25 it declined by around 7%, although it opened at $29.11, which is significantly above the IPO price. For the last year, the company had revenue of $46 million and a net loss of $0.51 per share, while for the first quarter of 2015, its revenue amounted to $15 million and a net loss of $1.05.

Aside from OrbiMed, other hedge funds among those that we track, have not disclosed holding shares of Glaukos, so far. We will keep monitoring the filings with the Securities and Exchange Commission to get a better idea regarding the hedge fund sentiment. According to the S-1 form of Glaukos Corp (NYSE:GKOS), among the principal stockholders are Domain Associates, Versant Ventures, and Frazier Healthcare with 9.8%, 10.2% and 8.4% of the outstanding stock respectively.

We don’t just track the latest moves of hedge funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research which showed that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests, and easily beating the most popular large-cap picks of funds, which nonetheless get the majority of their collective capital. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic only the very best ideas of the best fund managers on your own? Since the beginning of forward testing in August 2012, the Insider Monkey small-cap strategy has outperformed the market every year, returning 135.3%, nearly 2.5 times greater returns than the S&P 500 during the same period (see more details).

It’s not surprising that OrbiMed was among the investors that backed Glaukos Corp (NYSE: GKOS), when it was still a private company. Mr. Isaly is known for investing in companies from venture capital to public markets and is focused on companies that develop pharmaceutical products or medical devices, rather than different healthcare services. According to its latest 13F filing, OrbiMed’s equity portfolio stands at $11.71 billion, balanced between large- and small-cap companies. Earlier in May, OrbiMed disclosed slightly trimming its stake in biopharmaceutical company Relypsa Inc (NASDAQ:RLYP) to 7.40 million shares from 8.86 million shares, holding an activist stake with 17.90%. Moreover, the fund’s top positions are represented by Bristol-Myers Squibb Co (NYSE:BMY), Biogen Inc (NASDAQ:BIIB), and Amgen, Inc. (NASDAQ:AMGN).

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!